Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

European Biotechs Pushing the Frontiers in Immunotherapy

March 18, 2026

European biotech companies are exploring new therapeutic targets on T-cells to overcome drug resistance and improve clinical outcomes in cancer.

FDA Approves First Oral Peptide for Plaque Psoriasis

March 18, 2026

The FDA approves icotrokinra, the first targeted oral peptide blocking the IL-23 receptor, for moderate-to-severe plaque psoriasis with Phase III data across 2,500 patients.

Med Uni Graz and Boehringer Ingelheim Open Lung Cancer Research Lab

March 17, 2026

The new €3.2M (US$3.7M) research lab will investigate immunogenic cell death mechanisms in lung cancer to improve how existing therapies trigger immune response.

PharmTech Weekly Roundup–March 13, 2026

March 13, 2026

This week, the industry experienced accelerated digital transformation, regulatory evolution, and a strategic shift toward complex, patient-centric modalities.

Why Orphan Drugs Remain Resilient in a Shifting Market

March 13, 2026

Rare disease drugs are forecast to exceed $400B by 2032, driven by policy shifts and pipeline growth, despite competition from large-indication products.

SteinCares and Shilpa Biologicals Collaborate on Biosimilar Access for Latin America

March 11, 2026

The two companies have entered into a licensing agreement to commercialize biosimilars in Latin America.

What FDA's Leucovorin Decision Means for Pharma Developers

March 10, 2026

FDA approves leucovorin for cerebral folate deficiency, signaling how literature-based evidence can support rare disease approvals without clinical trials.

The Shift to Complex Modalities for Cancer Treatment

March 09, 2026

The industry is shifting toward increasingly complex, precision-driven modalities for the treatment of cancer.

European Commission Approves Dosing Regimen for Fabry Disease Treatment

March 09, 2026

The 2mg/kg every-4-weeks dosing regimen for pegunigalsidase alfa in adults with Fabry disease who are stable with an enzyme replacement therapy has been approved in Europe.

PharmTech Weekly Roundup–March 6, 2026

March 06, 2026

Developments across the sector highlight a period of rapid acceleration and structural modernization.